Company news

Aethlon Medical, Inc. news in 2024

Aethlon Medical, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu

December 19, 2024

Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update

November 12, 2024

Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia

November 10, 2024

Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024

November 5, 2024

Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit

October 7, 2024

Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India

September 18, 2024

Aethlon Medical to Present at Virtual Investor Conferences in September

September 16, 2024

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier® Cancer Trial

September 15, 2024

Aethlon Medical to Present at the Life Sciences Investor Forum September 19th

September 12, 2024

Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys

August 26, 2024

Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update

August 13, 2024

Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier® Cancer Trial

August 11, 2024

Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 14, 2024

August 5, 2024

Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update

June 26, 2024

Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024

June 20, 2024

Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial

June 17, 2024

Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies

June 2, 2024

Aethlon Medical Announces Pricing of $4.7 Million Public Offering

May 14, 2024

Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma

May 9, 2024

Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices

February 20, 2024

Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update

February 13, 2024

Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024

February 6, 2024

Calls in 2024

Decks in 2024